**Author details**

Željka Škunca Psychiatric Hospital, Ugljan, Croatia

\*Address all correspondence to: skunca.zeljka@gmail.com

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**87**

*B Cell Lymphomagenesis*

2010;**101**(3):573-557

Hematology. 2018;**6**

2018;**7**(9):4284-4295

2009;**94**(8):1109-1123

2009;**100**(2):233-237

**References**

*DOI: http://dx.doi.org/10.5772/intechopen.87241*

[9] Carbone A, Gloghini

[10] Ramiscal RR, Vinuesa

2014;**21**(4):260-269

2013;**252**(1):146-155

2018;**103**:1-36

A. Follicular dendritic cell in early lymphomas involving follicles. Advances in Anatomic Pathology.

CG. T-cell subsets in the germinal center. Immunological Reviews.

[11] McPhail E, Maurer MJ, Macon WR, Feldman AL, Kurtin PJ, Ketterling RP, et al. Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements. Haematologica.

[12] Li S, Weiss VL, Wang XJ, Desai PA, Hu S, Yin CC, et al. High-grade B-cell lymphoma with MYC rearrangement

rearrangements is associated with high P53 expression and a poor prognosis. The American Journal of Surgical Pathology. 2016;**40**(2):253-261

[13] Visco C, Tzankov A, Xu-Monette ZY, et al. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab CHOP Consortium Program Study. Haematologica.

and without BCL2 and BCL6

2013;**98**(2):255-263

2007;**92**(10):1297-1301

[15] Nguyen L, Papenhausen P, Shao H. The Role of c-MYC in B-cell

lymphomas: Diagnostic and molecular aspects. Genes (Basel). 2017;**8**(4):116

[14] Lin P, Medeiros LJ. Highgrade B-cell lymphoma/leukemia associated with t(14;18) and *8q24/ MYC* rearrangement: A neoplasm of germinal center immunophenotype with poor prognosis. Haematologica.

[1] Seto M, Honma K, Nakagawa M. Diversity of genome profiles in malignant lymphoma. Cancer Science.

[2] Jin MK, Hoster E, Dreyling M, Unterhalt M, Hiddemann W, Klapper W. Follicular dendritic cells in follicular lymphoma and types of non-Hodgkin lymphoma show reduced expression of CD23, CD3J5 and CD54 but no association with clinical outcome. Histopathology. 2011;**58**:586-592

[3] Carbone A, Gloghini A. Follicular dendritic cell in lymphomas of follicular origin. Atlas of Genetics and Cytogenetics in Oncology and

[4] Ma X, Zhong Y, Yan Zheng Y, Jiang J, Wang Y. Coexpression of CD5 and CD43 predicts worse prognosis in diffuse large B cell lymphoma. Cancer Medicine.

[5] Thakral B, Medeiros LJ, Desai P, Lin P, Yin CC, Tang G, et al. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH. European Journal of Hematology. 2017;**98**(4):415-421

[6] Bende RJ, van Maldegem F, van Noesel CJM. Chronic inflammatory disease, lymphoid tissue neogenesis and extranodal marginal zone B-cell lymphomas. Haematologica.

[7] Niitsu N, Okamoto M, Miura I, Hirano M. Clinical significance of *8q24/c-Myc* translocation in diffuse large B-cell lymphoma. Cancer Science.

[8] Swerdlow SH, Campo E, Pileri SA, Harris NL, Jaffe ES, Stein H. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;**127**:2375-2390
